Stromal Steroid 5 Alpha-Reductase 2 Promotes Prostate Growth through WNT5A-Lymphoid Enhancer-Binding Factor...

Area of Science:

• Urology
• Endocrinology
• Molecular Biology

Background:

• Steroid 5 α-reductase 2 (SRD5A2) is crucial for androgen metabolism and a therapeutic target for benign prostatic hyperplasia (BPH).
• The precise relationship between baseline SRD5A2 expression and prostate volume is not fully understood.
• SRD5A2's role in stromal-epithelial interactions influencing prostate growth requires further elucidation.

Purpose of the Study:

• To investigate the correlation between SRD5A2 expression and prostate volume.
• To explore the molecular mechanisms linking SRD5A2 to prostate growth, particularly its interaction with WNT5A and insulin-like growth factor 1 (IGF1) signaling.
• To identify novel therapeutic targets for BPH, especially in cases resistant to conventional therapies.

Main Methods:

• Analysis of SRD5A2 expression in human prostate tissues from clinical trials and biorepositories.
• Quantitative assessment and correlation analysis of SRD5A2, WNT5A, prostate volume, and signaling pathways.
• In vivo studies using Srd5a2-null mice and in vitro experiments involving SRD5A2 overexpression in prostate stromal cells.

Main Results:

• SRD5A2 expression strongly correlates with total prostate and transition zone volume.
• Stromal WNT5A expression is positively associated with SRD5A2, but dihydrotestosterone levels are not.
• SRD5A2 overexpression up-regulates WNT5A and IGF1 signaling, promoting stromal cell proliferation and paracrine epithelial growth.

Conclusions:

• SRD5A2 drives prostate growth via a stromal WNT5A-IGF1 paracrine signaling axis, independent of androgen levels.
• This pathway represents a novel therapeutic mechanism for benign prostatic hyperplasia.
• Findings suggest potential treatments for BPH patients resistant to standard 5 α-reductase inhibitor therapy.